RETALHO DE KARAPANDZIC E RETALHO DE BERNARDBURROW- WEBSTER NA RECONSTRUÇÃO DO LÁBIO INFERIOR

Autor: Ana Brinca, P. Andrade, Ricardo Vieira, Américo Figueiredo

Publikováno v: Revista da Sociedade Portuguesa de Dermatologia e Venereologia, Vol 69, Iss 2 (2011)

O carcinoma espinhocelular é a neoplasia maligna mais frequente dos lábios, e em cerca de 90% dos casos localiza-se no lábio inferior, devido à maior exposição cumulativa à radiação ultravioleta. Os autores apresentam duas técnicas cirúrgi

Externí odkaz: https://doaj.org/article/8dab95f3fb2b4217b375703c69f6be36

RETALHO DE KARAPANDZIC E RETALHO DE BERNARDBURROW- WEBSTER NA RECONSTRUÇÃO DO LÁBIO INFERIOR

Autor: Ricardo Vieira, Pedro Andrade, Américo Figueiredo, Ana Brinca

Publikováno v: Revista da Sociedade Portuguesa de Dermatologia e Venereologia, Vol 69, Iss 2 (2011)

O carcinoma espinhocelular é a neoplasia maligna mais frequente dos lábios, e em cerca de 90% dos casos localiza-se no lábio inferior, devido à maior exposição cumulativa à radiação ultravioleta. Os autores apresentam duas técnicas cirúrgi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71667866feb27c5e934424bb0ed74409
https://doi.org/10.29021/spdv.69.2.611

Retalho de Karapandzic e retalho de Bernard-Burrow-Webster na reconstrução do lábio inferior

Autor: Brinca,Ana, Andrade,Pedro, Vieira,Ricardo, Figueiredo,Américo

Publikováno v: Anais Brasileiros de Dermatologia v.86 n.4 suppl.1 2011
Anais brasileiros de dermatologia
Sociedade Brasileira de Dermatologia (SBD)
instacron:SBD

O carcinoma de células escamosas é a neoplasia maligna mais frequente dos lábios, e em cerca de 90% dos casos, localiza-se no lábio inferior, por causa da maior exposição cumulativa à radiação ultravioleta. Os autores apresentam duas técnic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3056::e27a76f58258e9f74203a574baef9735
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962011000700041

Pharmacological inhibition of METTL3 impacts specific haematopoietic lineages.

Autor: Sturgess K; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Yankova E; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK.; Milner Therapeutics Institute, University of Cambridge, Puddicombe Way, Cambridge, CB2 0AW, UK., Vijayabaskar MS; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Isobe T; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Rak J; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Kucinski I; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Barile M; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Webster NA; Storm Therapeutics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK., Eleftheriou M; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK.; Milner Therapeutics Institute, University of Cambridge, Puddicombe Way, Cambridge, CB2 0AW, UK., Hannah R; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Gozdecka M; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Vassiliou G; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Rausch O; Storm Therapeutics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK., Wilson NK; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Göttgens B; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK. bg200@cam.ac.uk.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK. bg200@cam.ac.uk., Tzelepis K; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK. kt404@cam.ac.uk.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK. kt404@cam.ac.uk.; Milner Therapeutics Institute, University of Cambridge, Puddicombe Way, Cambridge, CB2 0AW, UK. kt404@cam.ac.uk.; Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK. kt404@cam.ac.uk.

Publikováno v: Leukemia [Leukemia] 2023 Oct; Vol. 37 (10), pp. 2133-2137. Date of Electronic Publication: 2023 Jul 19.

Remodeling of the m ⁶ A RNA landscape in the conversion of acute lymphoblastic leukemia cells to macrophages.

Autor: Bueno-Costa A; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain., Piñeyro D; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain.; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), 28029, Madrid, Spain., García-Prieto CA; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Catalonia, Spain., Ortiz-Barahona V; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain., Martinez-Verbo L; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain., Webster NA; STORM Therapeutics Ltd, Cambridge, UK., Andrews B; STORM Therapeutics Ltd, Cambridge, UK., Kol N; Cancer Research Center and Wohl Institute for Translational Medicine, Chaim Sheba Medical Center, Tel-Hashomer, Israel.; Department of Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Avrahami C; Cancer Research Center and Wohl Institute for Translational Medicine, Chaim Sheba Medical Center, Tel-Hashomer, Israel.; Department of Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Moshitch-Moshkovitz S; Cancer Research Center and Wohl Institute for Translational Medicine, Chaim Sheba Medical Center, Tel-Hashomer, Israel.; Department of Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Rechavi G; Cancer Research Center and Wohl Institute for Translational Medicine, Chaim Sheba Medical Center, Tel-Hashomer, Israel.; Department of Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Esteller M; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain. mesteller@carrerasresearch.org.; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), 28029, Madrid, Spain. mesteller@carrerasresearch.org.; Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. mesteller@carrerasresearch.org.; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia, Spain. mesteller@carrerasresearch.org.

Publikováno v: Leukemia [Leukemia] 2022 Aug; Vol. 36 (8), pp. 2121-2124. Date of Electronic Publication: 2022 Jun 09.